Population Pharmacokinetics of Linezolid in Adults with Pulmonary Tuberculosis-Reference-Cited by-同舟云学术

Population Pharmacokinetics of Linezolid in Adults with Pulmonary Tuberculosis

Published:2009-09 Issue:9 Volume:53 Page:3981-3984
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

McGee Bryan¹²,Dietze Reynaldo³,Hadad David Jamil³,Molino Lucilia Pereira Dutra³,Maciel Ethel Leonor Noia³,Boom W. Henry⁴,Palaci Moises³,Johnson John L.⁴,Peloquin Charles A.¹²

Affiliation:

1. Infectious Disease Pharmacokinetics Laboratory, National Jewish Health, Denver, Colorado

2. School of Medicine, University of Colorado, Denver, Colorado

3. Núcleo de Doenças Infecciosas, Centro de Ciências da Saúde, Universidade Federal do Espírito Santo (UFES), Vitória, Brazil

4. Tuberculosis Research Unit, Department of Medicine, Case Western Reserve University School of Medicine and University Hospitals Case Medical Center, Cleveland, Ohio

Abstract

ABSTRACT Nineteen adults with pulmonary tuberculosis received linezolid (600 mg) once or twice daily in an early bactericidal activity trial. A one-compartment population model produced median values for the absorption rate constant, volume of distribution, and elimination rate constant of 1.5 h −1 , 29.6 liters, and 0.25 h −1 (once daily) and 2.7 h −1 , 32.1 liters, and 0.15 h −1 (twice daily). Linezolid administered twice daily produced higher values for free drug area under the concentration-time curve (AUC)/MIC and time above MIC. Both regimens achieved free AUC/MIC ratios > 100. Median times above the MIC for free drug were 100% (twice daily) and 63% (once daily).

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01378-08

Reference20 articles.

1. In Vitro Activities of Linezolid against Clinical Isolates of Mycobacterium tuberculosis That Are Susceptible or Resistant to First-Line Antituberculous Drugs

2. Bozdogan, B., and P. C. Appelbaum. 2004. Oxazolidinones: activity, mode of action, and mechanism of resistance. Int. J. Antimicrob. Agents23:113-119.

3. Bustad, A., D. Terziivanov, R. Leary, R. Port, A. Schumitzky, and R. Jelliffe. 2006. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies. Clin. Pharmacokinet.45:365-383.

4. Condos, R., N. Hadgiangelis, E. Leibert, G. Jacquette, T. Harkin, and W. N. Rom. 2008. Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis. Chest134:187-192.

5. Activities of Several Novel Oxazolidinones against Mycobacterium tuberculosis in a Murine Model

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rifampicin reduces plasma concentration of linezolid in patients with infective endocarditis;Journal of Antimicrobial Chemotherapy;2023-10-12

2. Linezolid Population Pharmacokinetic Model in Plasma and Cerebrospinal Fluid Among Patients With Tuberculosis Meningitis;The Journal of Infectious Diseases;2023-09-22

3. Linezolid population pharmacokinetic model in plasma and cerebrospinal fluid among patients with tuberculosis meningitis;2023-04-07

4. Influence of Antibiotics on Functionality and Viability of Liver Cells In Vitro;Current Issues in Molecular Biology;2022-10-03

5. Expert consensus statement on therapeutic drug monitoring and individualization of linezolid;Frontiers in Public Health;2022-08-10